drugset / Trial / NCT02086552
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2
Completed
28 enrolled
Mayo Clinic
National Cancer Institute (NCI) · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
Timeline
- Start
- 2014-01-17
- Primary completion
- 2018-01-15
- Completion
- 2021-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Sonidegib | Small molecule | — | Oral |